TY - JOUR
T1 - Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia
AU - Witjes, Wim P.J.
AU - Rosier, Peter F.W.M.
AU - De Wildt, Michel J.A.M.
AU - Van Iersel, Matheus P.
AU - Debruyne, Frans M.J.
AU - De La Rosette, Jean J.M.C.H.
PY - 1996/4
Y1 - 1996/4
N2 - Purpose: We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A total of 45 patients who participated in a multicenter trial was evaluated with urodynamic pressure-flow studies before and after 26 weeks of treatment. Results: Maximum flow rate and symptom score improved significantly in 22 patients with and 11 without bladder outlet obstruction who completed 26 weeks of treatment. In patients with bladder outlet obstruction the condition was significantly reduced and in patients without obstruction, significant urodynamic changes could not be detected. Conclusions: Terazosin treatment results in symptomatic relief and improved urinary flow in patients with and without bladder outlet obstruction, and in significant improvement in patients with urodynamically proved obstruction.
AB - Purpose: We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A total of 45 patients who participated in a multicenter trial was evaluated with urodynamic pressure-flow studies before and after 26 weeks of treatment. Results: Maximum flow rate and symptom score improved significantly in 22 patients with and 11 without bladder outlet obstruction who completed 26 weeks of treatment. In patients with bladder outlet obstruction the condition was significantly reduced and in patients without obstruction, significant urodynamic changes could not be detected. Conclusions: Terazosin treatment results in symptomatic relief and improved urinary flow in patients with and without bladder outlet obstruction, and in significant improvement in patients with urodynamically proved obstruction.
KW - prostate
KW - prostatic hyperplasia
KW - urodynamics
KW - adrenergic alpha receptor blockaders
UR - http://www.scopus.com/inward/record.url?scp=0029878038&partnerID=8YFLogxK
U2 - 10.1016/S0022-5347(01)66255-4
DO - 10.1016/S0022-5347(01)66255-4
M3 - Article
C2 - 8632523
SN - 0022-5347
VL - 155
SP - 1317
EP - 1323
JO - The Journal of Urology
JF - The Journal of Urology
IS - 4
ER -